Status:
COMPLETED
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Metastatic Colorectal Cancer (mCRC)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
Eligibility Criteria
Inclusion
- Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by:
- Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x)
- Pathology consistent with CRC
- At least two documented clinical visits on or after January 1, 2013
- Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013
- Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR)
- Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date
- Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study
Exclusion
- Participants \<18 years of age at index date
- Participants who received clinical trial drug during the prior or post periods
Key Trial Info
Start Date :
January 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT05420909
Start Date
January 28 2019
End Date
April 1 2019
Last Update
August 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Princeton, New Jersey, United States, 08543